Atea Pharmaceuticals, Inc. 8-K

What Happened

• Atea Pharmaceuticals (AVIR) filed a Form 8-K on January 8, 2026 to disclose a press release reporting the company’s preliminary unaudited cash and investments balance as of December 31, 2025. The press release is furnished as Exhibit 99.1 to the filing. This disclosure was made under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Filing date: January 8, 2026.
• Reporting item: Item 2.02 — preliminary unaudited cash and investment balance as of December 31, 2025.
• Press release furnished as Exhibit 99.1 to the Form 8-K.
• Information is preliminary and unaudited and may be subject to change when audited results are reported.

Why It Matters

• Cash and investment balances are key liquidity metrics that help investors assess the company’s runway to fund operations, clinical programs, and other activities.
• Because the figure disclosed is preliminary and unaudited, investors should treat it as an interim update and look for the company’s next periodic report (e.g., Form 10-Q or 10-K) or full earnings release for finalized audited numbers and additional context.
• Review the Exhibit 99.1 press release in the 8-K for the exact figure and any accompanying commentary from management.